GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (LTS:0D53) » Definitions » Total Liabilities

Financiere de Tubize (LTS:0D53) Total Liabilities : €123.65 Mil (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Financiere de Tubize Total Liabilities?

Financiere de Tubize's Total Liabilities for the quarter that ended in Dec. 2023 was €123.65 Mil.

Financiere de Tubize's quarterly Total Liabilities declined from Dec. 2022 (€87.19 Mil) to Jun. 2023 (€48.60 Mil) but then increased from Jun. 2023 (€48.60 Mil) to Dec. 2023 (€123.65 Mil).

Financiere de Tubize's annual Total Liabilities increased from Dec. 2021 (€54.42 Mil) to Dec. 2022 (€87.19 Mil) and increased from Dec. 2022 (€87.19 Mil) to Dec. 2023 (€123.65 Mil).


Financiere de Tubize Total Liabilities Historical Data

The historical data trend for Financiere de Tubize's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Financiere de Tubize Total Liabilities Chart

Financiere de Tubize Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 87.46 34.26 54.42 87.19 123.65

Financiere de Tubize Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.42 46.15 87.19 48.60 123.65

Financiere de Tubize Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Financiere de Tubize's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=122.715+(0+0.935
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=123.65

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=1920.244-1796.594
=123.65

Financiere de Tubize's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=122.715+(0+0.935
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=123.65

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=1920.244-1796.594
=123.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Financiere de Tubize Total Liabilities Related Terms

Thank you for viewing the detailed overview of Financiere de Tubize's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Financiere de Tubize (LTS:0D53) Business Description

Traded in Other Exchanges
Address
Allée de la Recherche, 60, Brussels, BEL, 1070
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Financiere de Tubize (LTS:0D53) Headlines

No Headlines